| Mrs Joanna Marie Nichols, LICENSED NURSE | |
|
1324 Ryanwood Ave, Memphis, TN 38116-8825 | |
| (901) 428-7601 | |
| Not Available |
| Full Name | Mrs Joanna Marie Nichols |
|---|---|
| Gender | Female |
| Speciality | Licensed Vocational Nurse |
| Location | 1324 Ryanwood Ave, Memphis, Tennessee |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518692037 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164X00000X | Licensed Vocational Nurse | 58707 (Tennessee) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Joanna Marie Nichols, LICENSED NURSE 1324 Ryanwood Ave, Memphis, TN 38116-8825 Ph: (901) 428-7601 | Mrs Joanna Marie Nichols, LICENSED NURSE 1324 Ryanwood Ave, Memphis, TN 38116-8825 Ph: (901) 428-7601 |
News Archive
The Lancet published a significant development for TB diagnostics yesterday with concrete and encouraging study outcomes on the effectiveness of the new Xpert MTB/RIF test for TB and rifampicin resistance in realistic health care field conditions. One of the authors, Prof. Mark Nicol of the University of Cape Town (South Africa) who contributed to this study, is an EDCTP Senior Fellow. The article demonstrates that the test can effectively be used in low-resource settings to simplify early and accurate diagnosis of patients. The potential impact is a reduction in the morbidity associated with diagnostic delay, dropout and mistreatment. The article has appeared online on 19 April 2011 and will be published in volume 377 on 30 April 2011.
A significant, sustained, global investment in treating children with cancer could save 11 million lives and yield a triple return on investment, according to a Lancet Oncology Commission report published by Lancet.
Agilent Technologies Inc. (NYSE:A) today announced that it has listed its Infinity Series 1200 liquid chromatography systems and 6000 Series mass spectrometry systems as Class I medical devices with the U.S. Food and Drug Administration.
In a new, multisite study of deaf children with cochlear implants, UT Dallas researchers have found that children with either no exposure or limited exposure to sign language end up with better auditory, speaking and reading skills later.
› Verified 7 days ago